Lifecore Biomedical, Inc. (LFCR) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
↑
N/A
—
5yr avg: 68.47
30Y Low8.8·High85.7
P/FCF
N/A
—
5yr avg: N/A
30Y Low11.4·High57.5
P/B Ratio
↑
124.32
↑+151% vs avg
5yr avg: 49.60
30Y Low0.7·High175.1
ROE
↓
-612.1%
↑-405% vs avg
5yr avg: -121.3%
30Y Low-238%·High339%
Debt/EBITDA
↑
N/A
—
5yr avg: 29.53
30Y Low0.0·High39.5
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
LFCR Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Lifecore Biomedical, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $179M | $234M | $206M | $238M | $291M | $351M | $311M | $284M | $394M | $387M | $314M |
| Enterprise Value | $301M | $357M | $331M | $331M | $538M | $565M | $532M | $435M | $464M | $436M | $366M |
| P/E Ratio → | -3.76 | — | 17.03 | — | — | — | — | 133.69 | 15.84 | 36.84 | — |
| P/S Ratio | 1.39 | 1.82 | 1.61 | 2.30 | 2.61 | 3.48 | 1.94 | 0.51 | 0.75 | 0.73 | 0.58 |
| P/B Ratio | 124.32 | 175.14 | 18.21 | — | 3.31 | 1.73 | 1.35 | 1.05 | 1.56 | 1.70 | 1.48 |
| P/FCF | — | — | — | — | — | — | — | — | — | 57.48 | — |
| P/OCF | — | — | 801.63 | — | — | 21.29 | — | 17.71 | 19.90 | 13.20 | 14.43 |
P/E links to full P/E history page with 30-year chart
LFCR EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.77 | 2.58 | 3.21 | 4.83 | 5.60 | 3.32 | 0.78 | 0.88 | 0.82 | 0.68 |
| EV / EBITDA | — | — | — | — | 85.75 | 51.19 | — | 66.04 | 19.47 | 16.64 | — |
| EV / EBIT | — | — | 12.00 | — | — | — | — | 49.07 | 34.12 | 27.23 | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | 64.69 | — |
LFCR Profitability
Margins and return-on-capital ratios measuring operating efficiency
Lifecore Biomedical, Inc. earns an operating margin of -13.4%. Operating margins have expanded from -21.1% to -13.4% over the past 3 years, signaling improving operational efficiency. A negative ROE of -612.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 31.3% | 31.3% | 32.6% | 27.1% | 35.1% | 38.6% | 24.6% | 14.5% | 14.9% | 15.6% | 13.1% |
| Operating Margin | -13.4% | -13.4% | -6.9% | -21.1% | -10.6% | -8.7% | -16.2% | -1.4% | 2.3% | 2.9% | -3.7% |
| Net Profit Margin | -30.0% | -30.0% | 9.4% | -96.4% | -104.9% | -32.0% | -23.9% | 0.4% | 4.7% | 2.0% | -2.2% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -612.1% | -612.1% | 339.1% | -238.2% | -80.3% | -14.9% | -15.2% | 0.8% | 10.3% | 4.8% | -5.4% |
| ROA | -15.7% | -15.7% | 4.7% | -37.7% | -30.0% | -6.2% | -7.2% | 0.5% | 6.5% | 3.0% | -3.4% |
| ROIC | -9.9% | -9.9% | -5.9% | -7.7% | -2.4% | -1.5% | -4.4% | -1.6% | 3.0% | 4.3% | -5.8% |
| ROCE | -8.1% | -8.1% | -4.1% | -14.0% | -4.7% | -2.3% | -6.8% | -2.3% | 3.8% | 5.2% | -6.9% |
LFCR Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $123M ($131M total debt minus $8M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 97.92 | 97.92 | 11.81 | — | 2.82 | 1.06 | 0.96 | 0.56 | 0.29 | 0.24 | 0.29 |
| Debt / EBITDA | — | — | — | — | 39.52 | 19.55 | — | 23.14 | 3.06 | 2.06 | — |
| Net Debt / Equity | — | 91.74 | 11.06 | — | 2.81 | 1.06 | 0.96 | 0.56 | 0.28 | 0.21 | 0.25 |
| Net Debt / EBITDA | — | — | — | — | 39.36 | 19.44 | — | 22.98 | 2.94 | 1.85 | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | 7.21 | — |
| Interest Coverage | -0.77 | -0.77 | 1.53 | -2.63 | -0.34 | -2.33 | -5.60 | 1.70 | 6.97 | 8.76 | -8.49 |
LFCR Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Lifecore Biomedical, Inc.'s current ratio of 2.84x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The quick ratio of 1.77x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has improved from 2.39x to 2.84x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.84 | 2.84 | 2.08 | 2.39 | 0.66 | 1.46 | 0.96 | 0.97 | 1.10 | 1.58 | 1.53 |
| Quick Ratio | 1.77 | 1.77 | 1.06 | 1.35 | 0.46 | 0.84 | 0.55 | 0.58 | 0.74 | 1.09 | 1.08 |
| Cash Ratio | 0.27 | 0.27 | 0.22 | 0.49 | 0.01 | 0.01 | 0.00 | 0.01 | 0.03 | 0.11 | 0.18 |
| Asset Turnover | — | 0.54 | 0.51 | 0.41 | 0.41 | 0.20 | 0.30 | 1.07 | 1.30 | 1.49 | 1.58 |
| Inventory Turnover | 2.74 | 2.74 | 2.16 | 1.84 | 2.01 | 0.98 | 1.82 | 8.80 | 14.01 | 17.76 | 18.41 |
| Days Sales Outstanding | — | 123.68 | 88.65 | 102.58 | 125.68 | 149.91 | 173.77 | 45.54 | 37.51 | 31.48 | 31.30 |
LFCR Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Lifecore Biomedical, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 5.9% | — | — | — | — | 0.7% | 6.3% | 2.7% | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | 1.7% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $35M | $37M | $30M | $29M | $29M | $29M | $29M | $28M | $28M | $27M |
Peer Comparison
Compare LFCR with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 LFCRYou | $179M | -3.8 | — | — | 31.3% | -13.4% | -612.1% | -9.9% | — |
 PCRX | $930M | 147.8 | 9.9 | 6.8 | 79.4% | 4.6% | 1.0% | 2.3% | 3.7 |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 ATRC | $1B | -115.8 | 77.7 | 29.2 | 74.4% | -0.6% | -2.4% | -0.6% | 5.2 |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 HOLX | $17B | 30.5 | 17.4 | 18.4 | 61.0% | 17.4% | 11.1% | 9.4% | 2.6 |
 ALGN | $12B | 29.8 | 13.9 | 24.6 | 68.3% | 15.3% | 10.4% | 15.4% | 0.1 |
 MMSI | $4B | 29.3 | 13.1 | 17.2 | 48.7% | 12.2% | 8.7% | 7.2% | 2.8 |
 ICUI | $3B | 4186.1 | 12.8 | 33.5 | 36.8% | 4.8% | 0.0% | 2.5% | 4.3 |
 BAX | $9B | -10.0 | 25.4 | 28.0 | 30.1% | -2.7% | -14.6% | -1.4% | 14.9 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 29 years · Updated daily
See LFCR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LFCR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LFCR vs PCRX
Side-by-side business, growth, and profitability comparison vs Pacira BioSciences, Inc..
Start ComparisonLFCR — Frequently Asked Questions
Quick answers to the most common questions about buying LFCR stock.
What is Lifecore Biomedical, Inc.'s P/E ratio?
Lifecore Biomedical, Inc.'s current P/E ratio is -3.8x. The historical average is 33.2x.
What is Lifecore Biomedical, Inc.'s ROE?
Lifecore Biomedical, Inc.'s return on equity (ROE) is -612.1%. The historical average is 0.6%.
Is LFCR stock overvalued?
Based on historical data, Lifecore Biomedical, Inc. is trading at a P/E of -3.8x. Compare with industry peers and growth rates for a complete picture.
What are Lifecore Biomedical, Inc.'s profit margins?
Lifecore Biomedical, Inc. has 31.3% gross margin and -13.4% operating margin.